8-K: Stereotaxis Reports 18% Revenue Increase in Third Quarter 2024, Driven by Robotic System Demand

Stereotaxis reported an 18% year-over-year revenue increase in the third quarter of 2024, driven by demand for its Genesis robotic systems and the acquisition of Access Point Technologies.

Summary

• Stereotaxis announced its financial results for the third quarter of 2024, showing a revenue of $9.2 million, an 18% increase compared to $7.8 million in the same quarter of the previous year.
• System revenue was $4.4 million, reflecting partial revenue recognition of three Genesis robotic systems, while recurring revenue reached $4.8 million.
• The company received orders for two Genesis systems and anticipates the first order for the GenesisX system soon.
• Stereotaxis has a system backlog of over $15 million, supporting continued revenue growth.
• The company achieved CE Mark approval for the GenesisX robotic system and is progressing with FDA submissions.
• The acquisition of Access Point Technologies (APT) is showing commercial and strategic value, with the manufacturing of hundreds of catheters for regulatory testing.
• A successful audit by the Chinese NMPA regulatory body indicates near-term approvals in China.
• Gross margin for the quarter was 45%, impacted by higher system revenue and acquisition-related accounting.
• Operating expenses were $10.4 million, including non-cash stock compensation and acquisition-related adjustments; adjusted operating expenses were $7.2 million.
• The operating loss was ($6.3) million, and the net loss was ($6.2) million, with adjusted losses of ($3.1) million and ($3.0) million, respectively.
• Negative free cash flow for the quarter was ($4.2) million.
• The company had $11.0 million in cash at the end of September, which increased to $13.3 million by the end of October due to significant cash receipts.
• Stereotaxis expects full-year revenue to be approximately equal to the previous year and anticipates ending the year with approximately $12 million in cash and no debt.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong revenue growth, successful acquisition integration, and progress on regulatory approvals. However, the operating and net losses, along with negative free cash flow, temper the overall optimism.

Positives

• Revenue increased by 18% year-over-year, indicating strong demand for the company's products.
• The company has a robust system pipeline and a backlog of over $15 million, suggesting future revenue growth.
• The acquisition of APT is showing commercial and strategic value, with successful integration and manufacturing of new products.
• The company has a strong cash position with $13.3 million in cash and no debt at the end of October.
• The company expects to reach profitability without the need for additional financing.
• The company is making broad progress on a new foundational product ecosystem.

Negatives

• The company reported an operating loss of ($6.3) million and a net loss of ($6.2) million for the quarter.
• Gross margin was impacted by a higher proportion of system revenue and acquisition-related accounting.
• The company had a negative free cash flow of ($4.2) million for the quarter.
• Operating expenses increased to $10.4 million, including non-cash items.

Risks

• The company's ability to manage expenses at sustainable levels is a risk.
• Acceptance of the company's products in the marketplace is a risk.
• Global economic conditions could affect customers' ability and willingness to purchase the technology.
• The company faces competitive factors and changes resulting from healthcare policy.
• The company is dependent upon third-party vendors.
• The timing of regulatory approvals is a risk.
• The impact of pandemics or other disasters is a risk.
• There is no assurance that the company will recognize revenue related to its purchase orders and other commitments.

Future Outlook

Stereotaxis expects full-year revenue to be approximately equal to the previous year and anticipates continued year-over-year revenue growth in both system and recurring revenue in the upcoming quarters. The company expects to end the year with approximately $12 million in cash and no debt and believes this will allow it to reach profitability without additional financing.

Management Comments

• The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline, said David Fischel, Chairman and CEO.
• We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company.
• The acquisition of APT in the third quarter is already demonstrating commercial and strategic value.
• We remain cognizant of the importance of maintaining financial strength and discipline.

Industry Context

The announcement reflects a growing trend in the medical device industry towards robotic surgery and minimally invasive procedures. Stereotaxis is positioning itself as a leader in this space, focusing on innovation and strategic acquisitions to expand its product offerings and market reach.

Comparison to Industry Standards

• While specific competitor results are not provided, Stereotaxis's 18% revenue growth is a positive sign in the competitive medical robotics market.
• Companies like Intuitive Surgical and Medtronic are key players in the surgical robotics space, and Stereotaxis is aiming to carve out a niche with its focus on endovascular procedures.
• The successful integration of APT and the progress on regulatory approvals are crucial for Stereotaxis to compete effectively.
• The company's cash position and expectation to reach profitability without additional financing are important factors for investors to consider in comparison to other companies in the sector.

Stakeholder Impact

• Shareholders will be impacted by the financial results and future outlook.
• Employees are impacted by the company's growth and strategic direction.
• Customers will benefit from the company's innovative products and services.
• Suppliers and creditors are impacted by the company's financial health and performance.

Next Steps

• The company expects to receive the first GenesisX order in the near future.
• European CE Mark approval of the MAGiC ablation catheter is expected in the near future.
• The company will continue engagement with the FDA on the MAGiC PMA submission.
• Regulatory approvals for the robotic high-density mapping catheter and vascular guidance catheter are expected next quarter.
• The company anticipates near-term approvals in China.

Key Dates

Keywords

surgical robotics, endovascular intervention, robotic systems, Genesis, GenesisX, MAGiC ablation catheter, Access Point Technologies, APT, revenue, financial results, CE Mark, FDA, regulatory approvals